PMID: 4904933Jan 24, 1970Paper

L-asparaginase in treatment of acute leukaemia and lymphosarcoma

British Medical Journal
M E BeardR B Scott

Abstract

L-Asparaginase was used to treat 40 patients with acute leukaemia or lymphosarcoma. Fifteen with acute lymphoblastic leukaemia either untreated or in relapse after previous therapy were given "Squibb," "Bayer," or "Porton" L-asparaginase. Five of these patients had complete remission of their disease, and four had good partial remission. Eleven patients with acute myeloid leukaemia were treated for a short period with L-asparaginase alone. None of them went into remission though a pronounced fall in the numbers of circulating white cells was seen. Six patients with lymphosarcoma received L-asparaginase, two of them having good partial remissions.The toxic side-effects of the L-asparaginase from the three sources seemed to vary, and L-asparaginase from Erwinia carotovora appeared to be antigenically different from the enzyme produced by Escherichia coli.The way in which leukaemic cells become resistant to the action of the enzyme requires further investigation. To overcome this resistance asparaginase should be used in combination with other drugs in the treatment of acute leukaemia.

References

Nov 29, 1968·Deutsche medizinische Wochenschrift·C G Schmidt, W M Gallmeier
May 1, 1964·Archives of Biochemistry and Biophysics·L T MASHBURN, J C WRISTON

❮ Previous
Next ❯

Citations

Aug 22, 2012·Bioprocess and Biosystems Engineering·David GervaisTrevor Marks
Apr 1, 1977·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P DujardinP Audoly
Oct 13, 1998·Critical Reviews in Oncology/hematology·H J Müller, J Boos
Apr 10, 2009·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Christina LeeWilliam B Klaustermeyer
Feb 1, 1971·Australian and New Zealand Journal of Medicine·J C BiggsJ Holliday
May 1, 1997·The Journal of Pharmacy and Pharmacology·F JameelD Kalonia
Oct 31, 1970·British Medical Journal·R B Scott
Jan 1, 1985·Cancer Investigation·R A Kempf, M S Mitchell
Jul 6, 2015·Journal of Molecular Biology·Andriy AnishkinSusan B Rempe
Aug 8, 2014·Annals of the New York Academy of Sciences·Wanda L SalzerStephen P Hunger
Jul 5, 1985·Journal of Molecular Biology·H L AmmonA Wlodawer
Oct 19, 2017·Chemphyschem : a European Journal of Chemical Physics and Physical Chemistry·N M F S A CerqueiraM J Ramos
Jan 15, 1971·Nature·D Crowther
Sep 13, 1972·Nature: New Biology·T Han, T Onuma
Jan 1, 1986·Archives of Virology·K C McCullough
May 1, 1989·Medical Toxicology and Adverse Drug Experience·A K BanerjeeS L Grainger
Sep 15, 1982·International Journal of Cancer. Journal International Du Cancer·J A DistasioD L Durden
Jul 29, 2017·Journal of Hematology & Oncology·Marcus Kwong Lam Fung, Godfrey Chi-Fung Chan
Dec 18, 2013·PLoS Neglected Tropical Diseases·Inês LoureiroAnabela Cordeiro-da-Silva
Apr 3, 2013·Journal of the American Chemical Society·Diana S GestoMaria J Ramos

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.